UCL spinout Engitix plans to develop therapeutics for liver fibrosis and certain cancers based on its targeted drug discovery platform.
Engitix, a UK-based drug discovery spinout from University of College London (UCL), closed a £5m ($6.4m) series A round yesterday led by an unnamed private investor.
Founded in 2016, Engitix has developed a drug discovery platform which uses specific engineered tissues to find treatments that target liver fibrosis, a condition affecting the liver’s function due to scarring, as well as certain liver and pancreatic cancers.
Engitix’s platform includes specimen drawn from the non-cellular component of specific tissues, a…
